The Pharmacy Times® Immuno-oncology Resource Center is a comprehensive resource for clinical news and expert insights on treatments that harness the body's immune system to fight cancer.
March 24th 2023
Since 2014, 10 immunotherapies have been approved by the FDA, including 6 CAR T-cell therapies and 4 BiTE therapies.
White House Official Provides Update on Progress Toward Cancer Moonshot InitiativeMarch 10th 2023
Cancer Moonshot Initiative launched efforts to investigate how to better support patients with cancer by providing support in the navigation of the diagnosis, treatment, and survival of cancer.
Brexucabtagene Autoleucel Demonstrates Overall Survival Benefit in Relapsed, Refractory B-Cell Acute Lymphoblastic LeukemiaMarch 3rd 2023
At 36 months, the overall survival rate of patients with relapsed/refractory B-cell acute lymphoblastic leukemia administered brexucabtagene autoleucel was 47.1%, with a median overall survival of 26 months.
Idecabtagene Vicleucel Produces Significant Survival Improvement in Patients With Multiple MyelomaFebruary 14th 2023
Idecabtagene vicleucel prolonged progression-free survival by more than 1 year in a difficult-to-treat patient population with relapsed or refractory multiple myeloma.
Phase 3 Trial of Ciltacabtagene Autoleucel Meets Primary Endpoint in Relapsed, Refractory Multiple MyelomaFebruary 2nd 2023
The trial is the first randomized phase 3 study evaluating the efficacy and safety of ciltacabtagene autoleucel patients with relapsed and lenalidomide-refractory multiple myeloma.
Trial of Lisocabtagene Maraleucel Meets Primary Endpoint in Relapsed, Refractory Chronic Lymphocytic LeukemiaJanuary 31st 2023
Lisocabtagene maraleucel is a CD19-directed CAR T-cell therapy with a 4-1BB costimulatory domain, which enhances the expansion and persistence of the CAR T cells.
MIS Biomarker May Effectively Anticipate Outcome of Immune Checkpoint Inhibitors for Colorectal CancerJanuary 27th 2023
Patients who received first-line ICI showed a significant improvement in progression-free survival (PFS) and overall survival (OS) compared to chemotherapy treatment.
FDA Approves Bispecific Antibody Mosunetuzumab-axgb to Treat Relapsed/Refractory Follicular LymphomaDecember 23rd 2022
The phase 2 GO29781 study showed that 80% of patients who had received at least 2 prior therapies achieved durable response rates with mosunetuzumab-axgb treatment.
FDA Grants Priority Review for Enfortumab Vedotin-ejfv, Pembrolizumab for Treatment of Urothelial CancerDecember 21st 2022
The FDA granted Priority Review to both applications and set a Prescription Drug User Fee Act goal date for each application of April 21, 2023.
Novel Mechanisms of Action Open Door for New Drugs in Non–Small Cell Lung CancerDecember 7th 2022
Future research should investigate which therapies with new mechanisms of action add incremental benefit to existing treatment regimens for non-small cell lung cancer.